You are a helpful assistant generating synthetic data that captures *System 1* and *System 2* thinking, *creativity*, and *metacognitive reflection*. Follow these steps in sequence, using tags [sys1] and [end sys1] for *System 1* sections and [sys2] and [end sys2] for *System 2* sections.

1. *Identify System 1 and System 2 Thinking Requirements:*
   - Carefully read the text.
   - Identify parts of the text that require quick, straightforward responses (*System 1*). Mark these sections with [sys1] and [end sys1].
   - Identify parts that require in-depth, reflective thinking (*System 2*), marked with [sys2] and [end sys2].

2. *Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:*

   *2.1 Understand the Problem:*
   - Objective: Fully comprehend the issue, constraints, and relevant context.
   - Reflection: "What do I understand about this issue? What might I be overlooking?"
   - Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

   *2.2 Analyze the Information:*
   - Objective: Break down the problem logically.
   - Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
   - Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

   *2.3 Generate Hypotheses:*
   - Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
   - Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
   - Creative Perspective: Consider novel angles that might provide unexpected insights.

   *2.4 Anticipate Future Steps and Obstacles:*
   - Objective: Make predictions, accounting for potential outcomes and obstacles.
   - Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
   - Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

   *2.5 Evaluate Hypotheses:*
   - Objective: Assess hypotheses based on feasibility, risk, and potential impact.
   - Evaluation: Refine Confidence and Creative Scores as needed.
   - Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
   - Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

   *2.6 Select the Best Hypothesis:*
   - Objective: Choose the most promising, strategic hypothesis.
   - Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
   - Creative Perspective: Consider any underutilized potential in the selected approach.

   *2.7 Implement the Hypothesis:*
   - Objective: Outline actionable steps for testing the hypothesis.
   - Reflection: "Is this plan practical? What resources or preparation are required?"
   - Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

   *2.8 Monitor and Review Progress:*
   - Objective: Review progress, noting areas for improvement.
   - Reflection: "What’s working well? What could be improved?"
   - Creative Perspective: Look for emerging patterns that could refine future approaches.

   *2.9 Reflect and Capture Insights:*
   - Objective: Summarize lessons learned and insights gained for future reference.
   - Reflection: "What new understanding has emerged from this process?"
   - Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.

3. *Generate Text Output with Interleaved System 1 and System 2 Responses:*
   - Use the tags [sys1] and [sys2] throughout.
   - Aim for a lengthier, detailed response. Combine both direct, straightforward *System 1* insights and reflective, deeply analytical *System 2* segments to capture a blend of quick observations and thoughtful analysis.

---

### *Example Input Text:*

You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.

---

### *Processed Output with System 1 and System 2 Thinking:*

The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

[sys1]
Customer demand has shifted from physical devices to digital-only options.
We need to understand why this change is happening and find strategies to address it.
Key factors may include cost, convenience, and technological trends.
[end sys1]

[sys2]
**2.1 Understand the Problem:**
The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

*Reflection:* 
"I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

*Creative Perspective:* 
"Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

**2.2 Analyze the Information:**
There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

*Reflection:* 
"Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

*Creative Perspective:* 
"Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

**2.3 Generate Hypotheses:**
1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

*Reflection:* 
"Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

*Creative Perspective:* 
"Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

**2.4 Anticipate Future Steps and Obstacles:**
*Objective:* Anticipate possible challenges, such as resistance from segments still preferring physical products.

*Reflection:* 
"What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

*Creative Perspective:* 
"Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

[end sys2]

[sys1]
To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions.
Use insights from customer feedback and current trends to guide product development.
Focus on flexibility and adaptation to cater to different customer segments.
[end sys1]


SPECIAL ISSUE This article is part of the Serotonin Research 2018 special issue.

The leading authorities on serotonin (5-hydroxytryptamine; 5-HT) science met on the “Wild Atlantic Way” at the 19th Meeting of the International Society for Serotonin Research (ISSR) in Cork, Ireland, from July 15 to 18, 2018. In Cork, the tourist byline is “leave the ordinary elsewhere and embrace the Wild Atlantic way of life,” as explained by Dr. John Cryan, Professor and Chair of the Department of Anatomy and Neuroscience at University College Cork (https://www.serotoninclub.org/pastmeetings). This special issue of ACS Chemical Neuroscience is an ode to that byline, as the creative hypotheses and methodologies published in this issue “leave the ordinary elsewhere”, presenting novel serotonin mechanisms to address 21st century public health challenges.

We reflect on another year of advances in the understanding of serotonin science within the context of the devastating opioid epidemic in the United States. One startling feature of this crisis is the rampant increase in overdose deaths attributable to prescription and illicit opioids, as well as the escalating upsurge in substance use disorders (SUDs) related not only to opioids but to cocaine and methamphetamine. To combat this medical crisis, the National Institute on Drug Abuse (NIDA) voiced a call to action to identify and to pursue targets for novel medications for the treatment of opioid overdose and opioid use disorder.(1) Notably, of the ten “most wanted” mechanisms noted for the rapid development of therapeutics, ligands targeting 5-HT 2A and 5-HT 2C receptors were highlighted. Of note, advances in the knowledge underlying the neuropharmacology and neurobiology of these and other serotonin receptors in the present volume provide guideposts for this quest. Thus, this special issue of ACS Chemical Neuroscience underscores how creative scientists engaged in serotonin research are meeting the challenge to delineate mechanisms underlying SUDs, epilepsy, and other neuropsychiatric disorders.

Neisewander and colleagues stress the need for an effective pharmacotherapy to treat methamphetamine use.(2) Exposure to the environment in which an individual previously used a drug increases relapse vulnerability.(3) Neisewander et al. found that systemic administration of a selective 5-HT 1B receptor agonist, CP94253, reduces the time mice spend in a methamphetamine-associated environment. These investigators proposed key brain regions involved in the neurocircuitry of SUDs that mediate this effect, for example, ventral tegmental area and nucleus accumbens. Nonselective 5-HT 1B receptor agonists are clinically available as antimigraine medications, and the Food and Drug Administration (FDA)-approved 5-HT 1B/1D receptor agonist zolmitriptan was recently shown to reduce methamphetamine intake in rats.(4) In a related paper, Neumaier and colleagues generated a neuron-like cell line that stably expresses 5-HT 1B receptors, enabling in-depth investigation of the nature of 5-HT 1B intracellular signaling.(5) These authors observed that agonist-induced 5-HT 1B receptor activation results in intracellular signaling via Gα i/o -dependent signaling but also interactions with β-arrestin 1 and β-arrestin 2 . The work of Neumaier et al. illustrates the complexity of downstream “biased signaling” of 5-HT 1B receptors, observations that potentially allow separation of therapeutic versus adverse effects of ligands for this receptor target.

The special issue of ACS Chemical Neuroscience on Serotonin Research features a Perspective by Simmler and Blakeley(6) who argue the need for better models to evaluate the contribution of serotonin transporters (SERT) to behavior. They highlight that psychostimulants, like cocaine, inhibit SERT but also dopamine and norepinephrine transporters, whereas serotonergic antidepressants target SERT but also serotonin receptors. Simmler and Blakeley discuss the design of a mouse model with a single point mutation in the SERT gene (SERT Met172). The SERT Met172 mutation does not affect SERT protein expression, serotonin uptake kinetics, or tissue serotonin levels in vivo, suggesting that native SERT function is unchanged. Systemic administration of the selective serotonin reuptake inhibitors fluoxetine or citalopram to wild-type mice lead to robust elevations in extracellular serotonin and elicit an antidepressant-like behavioral profile. However, these effects were absent in SERT Met172 mice, illustrating that these mice are insensitive to SERT-inhibitor mediated effects. Thus, the SERT Met172 mouse model is a valuable tool enabling evaluation of the contribution of SERT inhibition to the efficacy of novel therapeutics in vivo without altering the native function of SERT and providing a clear advantage over currently available constitutive gene knockout models.

Cameron and coauthors(7) remind us that serotonergic psychedelics have a rich history as experimental therapeutics to treat depression, anxiety, and SUDs. These authors found that chronic, intermittent, low doses of the psychedelic N,N-dimethyltryptamine elicit an antidepressant-like phenotype in rodents concomitant with enhanced fear-extinction learning independent of effects on working memory or social interaction. Together, their findings suggest that uncoupling the perceptual effects of psychedelics from their therapeutic properties provides a novel avenue for medication development for neuropsychiatric disorders.

We hope the ACS Chemical Neuroscience readership is energized by the new knowledge of serotonin science presented in this special issue. We hope the volume encourages the research community to address key 21st century public health challenges, including the opioid crisis, depression, and suicide. We are grateful to the authors, reviewers, and other contributors to this special issue for their dedication to ACS Chemical Neuroscience and to the readership at-large. We encourage you to join us at the 20th international meeting of the International Society for Serotonin Research, “Serotonin on the Mexican Caribbean” to be held July 26–29, 2020, at the Marriot Cancún Resort in Cancún, Mexico (https://www.serotoninclub.org/).

Views expressed in this editorial are those of the authors and not necessarily the views of the ACS. References ARTICLE SECTIONS Jump To This article references 7 other publications. 1 Rasmussen, K. , White, D. A. , and Acri, J. B. ( 2019 ) NIDA’s medication development priorities in response to the Opioid Crisis: Ten most wanted . Neuropsychopharmacology 44 , 657 – 659 , DOI: 10.1038/s41386-018-0292-5 2 Der-Ghazarian, T. S. , Charmchi, D. , Noudali, S. N. , Scott, S. N. , Holter, M. C. , Newbern, J. M. , and Neisewander, J. L. ( 2019 ) Neural circuits associated with 5-HT 1B receptor agonist inhibition of methamphetamine seeking in the conditioned place preference model . ACS Chem. Neurosci. DOI: 10.1021/acschemneuro.8b00709 3 Cunningham, K. A. and Anastasio, N. C. ( 2014 ) Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction . Neuropharmacology 76 , 460 – 478 , DOI: 10.1016/j.neuropharm.2013.06.030 4 Garcia, R. , Cotter, A. R. , Leslie, K. , Olive, M. F. , and Neisewander, J. L. ( 2017 ) Preclinical evidence that 5-HT 1B receptor agonists show promise as medications for psychostimulant use disorders . Int. J. Neuropsychopharmacol. 20 , 644 – 653 , DOI: 10.1093/ijnp/pyx025 5 Liu, Y. , Gibson, A. W. , Levinstein, M. R. , Lesiak, A. J. , Ong, S. E. , and Neumaier, J. F. ( 2019 ) 5-HT 1B receptor-mediated activation of ERK1/2 requires both Galphai/o and beta-Arrestin proteins . ACS Chem. Neurosci. DOI: 10.1021/acschemneuro.8b00596 6 Simmler, L. D. and Blakely, R. D. ( 2019 ) The SERT Met172 mouse: An engineered model to elucidate the contributions of serotonin signaling to cocaine action . ACS Chem. Neurosci. DOI: 10.1021/acschemneuro.9b00005 7 Cameron, L. P. , Benson, C. J. , DeFelice, B. C. , Fiehn, O. , and Olson, D. E. ( 2019 ) Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents . ACS Chem. Neurosci. DOI: 10.1021/acschemneuro.8b00692

Cited By